Commonwealth Equity Services LLC Sells 898 Shares of IDEXX Laboratories, Inc. $IDXX

Commonwealth Equity Services LLC lowered its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 17,407 shares of the company’s stock after selling 898 shares during the period. Commonwealth Equity Services LLC’s holdings in IDEXX Laboratories were worth $11,121,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Asset Management One Co. Ltd. grew its position in shares of IDEXX Laboratories by 0.4% during the 3rd quarter. Asset Management One Co. Ltd. now owns 55,837 shares of the company’s stock worth $35,674,000 after buying an additional 217 shares during the period. Moss Adams Wealth Advisors LLC boosted its stake in IDEXX Laboratories by 3.3% during the third quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock worth $337,000 after acquiring an additional 17 shares in the last quarter. Global Retirement Partners LLC boosted its stake in IDEXX Laboratories by 26.4% during the third quarter. Global Retirement Partners LLC now owns 561 shares of the company’s stock worth $358,000 after acquiring an additional 117 shares in the last quarter. Financiere des Professionnels Fonds d investissement inc. grew its holdings in IDEXX Laboratories by 31.4% in the third quarter. Financiere des Professionnels Fonds d investissement inc. now owns 360 shares of the company’s stock worth $230,000 after purchasing an additional 86 shares during the period. Finally, Signaturefd LLC increased its stake in IDEXX Laboratories by 6.8% in the third quarter. Signaturefd LLC now owns 1,457 shares of the company’s stock valued at $931,000 after purchasing an additional 93 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Up 0.1%

Shares of NASDAQ:IDXX opened at $713.35 on Monday. The business’s 50 day moving average is $706.93 and its 200 day moving average is $644.64. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98. The stock has a market cap of $56.96 billion, a price-to-earnings ratio of 56.57, a PEG ratio of 3.81 and a beta of 1.67. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 0.24.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period last year, the business earned $2.80 EPS. The business’s revenue was up 13.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several research reports. Barclays assumed coverage on IDEXX Laboratories in a research note on Monday, December 8th. They issued an “overweight” rating and a $850.00 target price for the company. Leerink Partners set a $785.00 price objective on IDEXX Laboratories in a research note on Monday, November 3rd. JPMorgan Chase & Co. upped their target price on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Weiss Ratings reissued a “hold (c+)” rating on shares of IDEXX Laboratories in a research report on Monday, December 29th. Finally, Stifel Nicolaus set a $775.00 price target on shares of IDEXX Laboratories in a research note on Monday, November 3rd. Seven equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $763.50.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the company’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the sale, the executive vice president directly owned 21,149 shares of the company’s stock, valued at approximately $14,874,937.66. This represents a 30.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.